XXXX and @entity15 in the era of disease-modifying treatments.

@entity1 @entity15093 @entity5 @entity1489 @entity792 @entity15
Prior to the era of disease-modifying therapies ( @entity15093 ), @entity15 ( @entity15 ) was linked to reduced rates of @entity5 . Early use of immunosuppressors (IS) in @entity15 justifies the follow-up of @entity1 to evaluate a possible increase in the incidence of @entity5 in these @entity1 . We performed a descriptive study of @entity15 @entity1 with a documented oncological event. Among the 22,563 @entity15 @entity1 in the EDMUS databases, @entity1 with a history of @entity5 were identified, and @entity5 risk in a @entity15 cohort (CARIMS) was evaluated. Four groups were defined: (A) @entity15 @entity1 without @entity5 receiving @entity15093 or not, (B) @entity15 @entity1 with @entity5 but without any history of @entity15093 , (C) @entity15 @entity1 with @entity5 who received an immunomodulator (IM), and/or (D) @entity15 @entity1 treated with an IS. A total of 9,269 @entity1 (44.1%) had a history of @entity15093 (52% IM; 18% IS; 30% both); 253 @entity1 with @entity15 and @entity5 were identified, 182 had a history of @entity15093 . The mean duration of @entity15093 was longer for group D (A: 3.6 years vs. D: 4.9 years; P < 0.01). There was no increased risk of @entity5 among @entity1 treated exclusively with IM. IS treatment (P = 0.043) and the duration of exposure (P < 0.001) significantly increased the risk of @entity5 , especially @entity1489 , as observed in other @entity792 . This result could influence the attitude of the medical profession with respect to the benefit to risk ratio when proposing @entity15093 to @entity15 @entity1 .
